Finance Watch: 2018 Biopharma VC Investment Could Beat 2017 One Quarter Ahead Of Schedule

With biopharma venture capital investment of $9.67bn during the first half, 2018's total is on track to beat 2017 in the third quarter. IPOs, one of the factors fueling VC investment, continue to boom with five more drug developers slated to go public this week.

Finance Watch

Venture capital investment in biopharmaceutical companies totaled $9.7bn in the first half of this year, so if the pace of $4.8bn per quarter keeps up, 2018 will beat the $12.4bn invested in private drug development firms in 2017 before the end of the third quarter.

PitchBook and the National Venture Capital Association (NVCA) noted several trends behind soaring venture capital investment in their quarterly Venture...

More from Financing

More from Business